CYAN 7.50 Cyanotech Corp $CYAN Hit a 52 week high of 7.50

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
CYAN 7.50 Cyanotech Corp $CYAN Hit a 52 week high of 7.50 Closing the day 09:41 at 7.50 +0.47 +6.69% With a day low of 7.25 and a total volume of 11,221.

CYAN Recent Posts: http://investorshangout.com/Cyanotech-Corp-CYAN-53859/

CYAN Cyanotech Corp Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NVEE: 11.90 (+1.41), SSO.TO: 5.91 (-0.03), BRDR: 8.01 (-0.02), CYAN: 7.25 (+0.22), SSRI: 5.23 (-0.02), SZMK: 6.17 (+0.09), AREX: 12.05 (-0.95)

Nasdaq stocks posting largest volume increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HEAR: 3.93 (-0.03), LSBK: 13.00 (+0.25), VSAR: 18.99 (+0.45), SANW: 3.62 (-0.04), URRE: 2.26 (-0.02), EDUC: 4.16 (-0.13), MCEP: 15.66 (-0.51), CYAN: 7.25 (+0.22), DNDN: 0.13 (+0.02), SUMR: 2.85 (-0.02), CRTN: 4.30 (unch)

Midday gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:45AM CST

FSM: 4.44 (+0.01), HEAR: 3.93 (-0.03), JRJC: 6.86 (-0.49), CVO: 1.79 (-0.02), AAOI: 12.03 (-0.14), UNIS: 2.83 (-0.06), HIIQ: 7.86 (-0.39), CYAN: 7.25 (+0.22), PTX: 11.00 (+0.05), TRMR: 2.71 (-0.10), PRKR: 1.13 (unch), SUMR: 2.85 (-0.02), VSLR: 11.67 (-0.26), RVP: 4.28 (+0.40), ASCMA: 53.99 (-0.21), ICUI: 85.67 (-0.04), CALL: 8.86 (+0.24), DMD: 5.43 (-0.22), AST: 3.93 (+0.13), ASEI: 46.35 (+0.23)

Cyanotech EPS of $0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:31PM CST

CYAN: 7.25 (+0.22)

Cyanotech Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2015
Business Wire - Mon Nov 10, 6:15PM CST
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal year 2015, ended September 30, 2014.
CYAN: 7.25 (+0.22)

Cyanotech Adds 2,280 Solar Array Panels; Reduces Greenhouse Emissions by 791 Metric Tons of Carbon Dioxide Per Year and Annual Electricity Costs by 10 Percent
Business Wire - Fri Oct 31, 12:10PM CDT
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a global producer of effective, natural microalgae nutritional supplements, announced the installation of its new solar array by Neighborhood Power Company (NPC). The 2,280 panel array sits on 1.3 acres of Cyanotech's 90-acre microalgae farm, and will produce 1,147,000 kilowatt hours of electricity each year, which Cyanotech will purchase under a Power Purchase Agreement (PPA). The energy production is sufficient to power the entire farm's production during daylight hours, and will reduce Cyanotech's electricity costs by 10 percent.
CYAN: 7.25 (+0.22)

Cyanotech Names Gerry Watts as Chief Operations Officer
Business Wire - Mon Aug 18, 7:00AM CDT
Cyanotech Corporation (Nasdaq Capital Market: CYAN) has named Gerard "Gerry" Watts to fill a newly-created position as Chief Operations Officer, effective today.
CYAN: 7.25 (+0.22)

Cyanotech Reports Financial Results for the First Quarter of Fiscal Year 2015
Business Wire - Thu Aug 14, 7:00AM CDT
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal year 2015, ended June 30, 2014.
CYAN: 7.25 (+0.22)

Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2014
Business Wire - Fri Jun 27, 8:00AM CDT
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the fourth quarter and fiscal year 2014, ended March 31, 2014.
CYAN: 7.25 (+0.22)

TerraX Closes Private Placement for $675,000
Marketwire - Wed Feb 12, 2:10PM CST
TerraX Minerals Inc. (TSX VENTURE: TXR)(FRANKFURT: TX0) has closed its previously announced non-brokered private placement of 1,500,000 units at $0.45 per unit, with two placees, for gross proceeds of $675,000. Each unit consists of one common share and one-half of one share purchase warrant, with each full warrant entitling the holder to purchase an additional common share at an exercise price of $0.51 per share until February 12, 2016. The shares and any shares acquired on the exercise of warrants will be subject to a hold period expiring on June 13, 2014. Finders' fees of $31,500 were paid with respect to this placement along with the issuance of 70,000 finders' warrants exercisable at $0.51 until February 12, 2016.
CYAN: 7.25 (+0.22), FMC: 56.55 (-0.07), TXR.VN: 0.310 (+0.010)

Cyanotech Reports Financial Results for the Third Quarter of Fiscal Year 2014
Business Wire - Thu Feb 06, 7:00AM CST
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the third quarter and first nine months of fiscal year 2014, ended December 31, 2013.
CYAN: 7.25 (+0.22)

Cyanotech Corporation names Walter B. Menzel as director
M2 - Mon Sep 09, 4:34AM CDT
The stockholders of Cyanotech Corporation (Nasdaq Capital Market: CYAN), a microalgae technology company, announced on Friday the appointment of Walter B. Menzel as its director.
CYAN: 7.25 (+0.22)

Cyanotech Stockholders Elect Walter B. Menzel as a Director
Business Wire - Fri Sep 06, 12:00PM CDT
Stockholders of Cyanotech Corporation (Nasdaq Capital Market: CYAN) elected Walter B. Menzel as a Director at the Annual Meeting on August 29, 2013.
CYAN: 7.25 (+0.22)

OTC Daily Alert Stock Watch Cyanotech Corporation (NASDAQ: CYAN)
WorldStockWire - Mon Sep 02, 5:16PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CYAN: 7.25 (+0.22)

Cyanotech Corp. (CYAN) Stock Research Links

CYAN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 4

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Soleno Therapeutics Celebrates FDA Approval of VYKAT XR for PWS

Updated Category News Views 420

Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...

Continue Reading
aTyr Pharma Faces Legal Challenges: Investors Urged to Act

Updated Category News Views 173

aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...

Continue Reading
Primo Brands Boosts Share Repurchase Program by $50 Million

Updated Category News Views 145

Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...

Continue Reading
GOTRAX Partners with RSMG Select to Inspire Youth Movement

Updated Category News Views 83

GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...

Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025

Updated Category News Views 245

Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...

Continue Reading